Abstract
Neuroendocrine tumors tend to grow slowly and are notoriously difficult to localize, at least in the early stages. Metastases are in most cases already present at the time of diagnosis. Somatostatin receptor scintigraphy improves detection of small and occult NET tumors. Intraoperative probe counting with a hand-held gamma probe can identify tumors even when they are small and impalpable, but receptor positive. This advanced operative approach may improve the survival of these patients.
MeSH terms
-
Biomarkers, Tumor / analysis
-
Diagnostic Imaging / methods*
-
Humans
-
Indium Radioisotopes
-
Magnetic Resonance Imaging / methods
-
Neoplasm Staging / methods
-
Neuroendocrine Tumors / diagnostic imaging
-
Neuroendocrine Tumors / drug therapy
-
Neuroendocrine Tumors / secondary
-
Neuroendocrine Tumors / surgery*
-
Positron-Emission Tomography / methods
-
Postoperative Care
-
Radiography, Interventional / methods*
-
Radiopharmaceuticals
-
Receptors, Somatostatin / analysis
-
Sensitivity and Specificity
-
Somatostatin / analogs & derivatives
-
Tomography, Emission-Computed, Single-Photon / methods
-
Ultrasonography
Substances
-
Biomarkers, Tumor
-
Indium Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Somatostatin
-
Somatostatin
-
pentetreotide